



Medi-Cal Rx

Preparing for Reinstatement: Test Your Knowledge

March 13, 2023

Test Your Knowledge

Below you will find a series of scenarios and possible answers to test your understanding of when prior authorizations (PAs) must be submitted, may be submitted, and for whom based on beneficiary age and enrollment eligibility. Select the best choice. After you have completed the test, you can review the correct answers at the end of this document with an explanation.

We hope you find this tool beneficial and welcome all feedback.

Questions

- 1. The date is March 25, 2023. The beneficiary is 21 years of age and is due for a renewal prescription for a continuous glucose monitoring (CGM). A check of the Covered Products List indicates that the product is covered. A check of the Approved NDC List indicates that the PA requirement for this product was reinstated during Phase II, Wave 2 (P2/W2).**
 - a. A PA must be submitted because Reinstatement Phase III: Retirement of the Transition Policy has been initiated.
 - b. A PA must be submitted because, under P2/W2, PA requirements for medical supplies have been reinstated.
 - c. A PA may be submitted because it is past February 24, 2023, when PAs may be submitted in advance of the original PA end date.
 - d. A PA is not required and should not be submitted because PA requirements have not been reinstated for beneficiaries aged 21 and younger.
- 2. The date is April 28, 2023. The beneficiary is 14 years of age and is receiving a first-time prescription for Wixela Inhub®. The beneficiary is not enrolled in California Children's Services (CCS). A check of the Approved NDC List indicates that the PA requirement for this drug class was reinstated during P2/W2. A search of the Contract Drugs List (CDL) confirms that the medication is not on the CDL.**
 - a. A PA must be submitted because Reinstatement Phase III: Retirement of the Transition Policy has been completed.
 - b. A PA must be submitted because the beneficiary is not enrolled in CCS.
 - c. A PA must be submitted because this is a new start prescription.
 - d. A PA is not required and should not be submitted because PA requirements have not been reinstated for beneficiaries aged 21 and younger.

- 3. The date is March 18, 2023. The beneficiary is 35 years of age and is due for renewal prescription for a CGM, last filled March 25, 2022, after being diagnosed with Type 2 diabetes. A check of the Covered Products List indicates that the product is covered with a Code 1 restriction for DM Type 1. A check of the Approved NDC List indicates that the PA requirement for this product was reinstated during P2/W2.**
- a. A PA should not be submitted as the beneficiary is not eligible for a CGM.
 - b. A PA may be submitted for review prior to the applicable transition lift to determine if the beneficiary is eligible for the CGM based on medical necessity.
 - c. The beneficiary must be transitioned to an alternate therapy on the Covered Products List.
 - d. A PA is not required at this time as the claim will pay under the Transition Policy.
 - e. Both b and d.
- 4. The date is April 3, 2023. The beneficiary is 52 years of age and is due for a renewal prescription for an anti-Parkinson's medication, Duopa® Suspension. The last renewal was October 25, 2022. A check of the Approved NDC List indicates that PA requirement for this drug class was reinstated during Phase II, Wave 1 (P2/W1) but is not part of Phase III, Lift 1 (P3/L1). A search of the CDL confirms that it is not on the CDL.**
- a. A PA must be submitted as the beneficiary is an adult.
 - b. A PA is not required because the medication was not part of the P3/L1 set of drug classes and is still covered under the Transition Policy.
 - c. A PA may be submitted for review prior to the applicable transition lift even though the prescription is covered under the Transition Policy.
 - d. A PA is required because the drug is not on the CDL.
 - e. Both b and c.
- 5. The date is March 30, 2023. The beneficiary is 22 years of age and has been newly prescribed Bethkis®. The beneficiary has cystic fibrosis and is enrolled in Genetically Handicapped Persons Program (GHPP). A search of the CDL confirms that it is not on the CDL. The Approved NDC List indicates that the PA requirement for this drug class was reinstated during P2/W1 but is not part of P3/L1.**
- a. A PA is not required because the beneficiary is enrolled in GHPP.
 - b. A PA is required because this medication is not on the CDL, and the beneficiary is 22 years of age.
 - c. A PA is required because this is a new start medication.
 - d. A PA is not required because the drug class is not under P3/L1.
 - e. Both b and c.

Answer Key

Answer Key	
Answer	Explanation
1. D	A PA is not required and should not be submitted because PA requirements have not been reinstated for beneficiaries aged 21 and younger. PA requirements for children and youth will be reinstated during Phase IV, which will begin no sooner than July 2023.
2. D	A PA is not required and should not be submitted because PA requirements have not been reinstated for beneficiaries aged 21 and younger. Although this is a new start medication, PA requirements for children and youth will be reinstated during Phase IV, which will begin no sooner than July 2023.
3. E	A PA may be submitted to determine if the beneficiary is eligible for the CGM based on medical necessity. However, a PA is not yet required as the claim will be paid under the Transition Policy. Answers B and D are both correct.
4. E	A PA may be submitted in advance of retirement of the Transition Policy but is not required because the drug class is not impacted by P3/L1. The claim will be paid under the Transition Policy. Answers B and C are both correct.
5. E	A PA is required because the medication is not on the CDL, the beneficiary is 22 years of age (that is, not exempt from PA reinstatement requirements), and this is a new start prescription (that is, not covered under the Transition Policy). Answers B and C are both correct.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.